Droxidopa

Subscribe to Selected New Research on Droxidopa

61 relevant articles (14 outcomes, 5 trials/studies) found for this Bio-Agent

Description: A precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Administration of DL-threo-3,4-dihydroxyphenylserine has been claimed to result in an improvement in this phenomenon but controlled studies have failed to demonstrate improvement. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Also Known As:

3,4-threo-DOPS; DL-threo-3,4-Dihydroxyphenylserine; Droxidopa, (DL-Tyr)-Isomer; erythro-3,4-Dihydroxyphenylserine; threo-DOPS; 3,4 Dihydroxyphenylserine; 3,4 threo DOPS; DL threo 3,4 Dihydroxyphenylserine; erythro 3,4 Dihydroxyphenylserine; threo DOPS; 3,4-Dihydroxyphenylserine; L-Tyrosine, beta,3-dihydroxy-, threo-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 42

Amines: 1264

Catecholamines: 5759

Epinephrine: 8858

Norepinephrine: 11174

Droxidopa: 61

3-(3,4-dihydroxyphenyl)-N-methylserine

Biogenic Amines: 672

Biogenic Monoamines: 24

Catecholamines: 5759

Norepinephrine: 11174

Droxidopa: 61

3-(3,4-dihydroxyphenyl)-N-methylserine

Amino Acids, Peptides, and Proteins

Amino Acids: 8786

Serine: 2425

Droxidopa: 61

3-(3,4-dihydroxyphenyl)-N-methylserine

Experts

1.	Kaufmann, Horacio: 1 article (03/2008)
2.	Mathias, Christopher J: 1 article (03/2008)
3.	Aragishi, A: 1 article (08/2001)
4.	Braune, S: 1 article (08/2001)
5.	Watson, L: 1 article (08/2001)
6.	Mathias, C J: 1 article (08/2001)
7.	Taylor, M D: 1 article (08/2001)
8.	Keeling, J E: 1 article (08/2001)
9.	Senard, J M: 1 article (08/2001)
10.	Kurihara, J: 1 article (12/2000)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/1997 - "Furthermore, L-threo-DOPS, nor-adrenergic precursor drug, is sometimes effective for the advanced stage of Parkinson's disease. " 02/01/1998 - "Effects of L-threo-Dops (Dops) administration on orthostatic hypotention were evaluated with changes in blood pressure by postural change (lying to standing position) and subjective symptoms in 15 patients of Parkinson's disease having symptoms of orthostatic hypotention. " 01/01/1997 - "L-threo-DOPS was a poor precursor for NA and also failed to influence extracellular DA in striatum, questioning its use in the treatment of freezing gait in late stages of Parkinson's disease." 01/01/1989 - "Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease." 10/01/1987 - "The effect of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) on synaptic transmission to the soleus motoneurons was studied using the H-reflex method in 12 normal subjects and in 4 patients with Parkinson's disease. " Order ALL the reference details at left...
2.	Orthostatic Hypotension (Postural Hypotension) 03/01/1999 - "The enhanced responses of these vasoactive mediators by L-threo-DOPS during head-up tilt may contribute to the improvement in orthostatic hypotension in patients with MSA." 08/01/2001 - "Following a one-week run-in, patients (26 MSA; 6 PAF) with symptomatic orthostatic hypotension received increasing doses of L-threo-DOPS (100, 200 and 300 mg, twice daily) in an open, dose-ranging study. " 03/01/2008 - "L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience." 03/01/2008 - "L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience." 08/01/2001 - "The dosage of 300 mg twice daily L-threo-DOPS seemed to offer the most effective control of symptomatic orthostatic hypotension in MSA and PAF." Order ALL the reference details at left...
3.	Polyneuropathies (Polyneuropathy) 05/01/1988 - "The case is reported of a 57-year-old woman with familial amyloidotic polyneuropathy and concomitant orthostatic hypotension for which L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) was clinically effective. " 07/01/1991 - "The effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS), an unnatural norepinephrine precursor, on alpha 2-adrenergic receptors in platelet membranes were investigated in a patient with familial amyloidotic polyneuropathy, two patients with multiple system atrophy, and two patients with Parkinson's disease. " Order ALL the reference details at left...
4.	Dementia (Dementias) 12/20/1991 - "L-threo-DOPS may be effective for treating some type of mental disorders, including dementia. " 03/01/1988 - "[The effective of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in hypersomnia and subcortical dementia caused by bilateral medial thalamic and midbrain infarcts]" Order ALL the reference details at left...
5.	Pseudobulbar Palsy 10/01/1994 - "Furthermore, additional administration of L-dopa and droxidopa improved his pseudobulbar palsy, akinesia, and lack of initiative. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Droxidopa
2.	Norepinephrine (Noradrenaline)
3.	Levodopa (L Dopa)
4.	Dopamine (Intropin)
5.	Aromatic Amino Acids (Aromatic Amino Acid)
6.	Dopa Decarboxylase
7.	Atrial Natriuretic Factor (ANF)
8.	P-300
9.	Harmaline
10.	Carbidopa (Lodosyn)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Oral Administration

Best Treatments:
Research Summary Report
on Parkinson Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1228 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>